Synovial Sarcoma Clinical Trial Pipeline Shows Potential With Active Contributions From 15+ Key Companies Delveinsight

DelveInsight's,“ Synovial Sarcoma Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative pipeline today! @ Synovial Sarcoma Pipeline Outlook

Key Takeaways from the Synovial Sarcoma Pipeline Report

• On February 25, 2026, Advenchen Laboratories LLC announced a study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.
• On February 25, 2026, USWM CT, LLC initiated a clinical trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
• DelveInsight's Synovial Sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Synovial Sarcoma treatment.
• The leading Synovial Sarcoma Companies such as Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
• Promising Synovial Sarcoma Pipeline Therapies such as TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.

Download for updates and be a part of the revolution in oncology care @ Synovial Sarcoma Clinical Trials Assessment

Synovial Sarcoma Emerging Drugs Profile

• AL3818: Advenchen Laboratories

Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1–4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.

• Tazemetostat: Ipsen

Tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process. Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of“relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of synovial sarcoma.

• DS-2243a: Daiichi Sankyo

DS-2243a is an investigational bispecific T-cell engager (BiTE) developed by Daiichi Sankyo, currently being studied for the treatment of advanced synovial sarcoma. This agent is designed to target tumors that express the HLA-A2 molecule and the cancer-testis antigen NY-ESO, both of which are commonly found in synovial sarcoma cells. By binding to both the tumor antigen and cytotoxic T lymphocytes, DS-2243a aims to direct the patient's immune system specifically against synovial sarcoma cells, potentially improving the body's ability to recognize and kill these cancerous cells. The ongoing Phase I clinical trial is focused on evaluating the safety, tolerability, and initial signs of efficacy of DS-2243a in patients with advanced synovial sarcoma who have limited treatment options.

The Synovial Sarcoma Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
• Synovial Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.

Learn more about Synovial Sarcoma Drugs opportunities in our groundbreaking Synovial Sarcoma research and development projects @ Synovial Sarcoma Unmet Needs

Synovial Sarcoma Companies

Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.

Synovial-Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Synovial Sarcoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we're transforming the future of oncology @ Synovial Sarcoma Market Drivers and Barriers, and Future Perspectives

Scope of the Synovial Sarcoma Pipeline Report

• Coverage- Global
• Synovial Sarcoma Companies- Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
• Synovial Sarcoma Pipeline Therapies- TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.
• Synovial Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Synovial Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Synovial Sarcoma Pipeline on our website @ Synovial Sarcoma Emerging Drugs and Companies

Table of Contents